BIOVECTRA ANNOUNCES APPOINTMENT OF GORDON C. MCCAULEY AND STEVEN M. KLOSK TO BOARD

Charlottetown, P.E.I. (October 21, 2021) – BIOVECTRA, a leading Canadian biotech and pharmaceutical CDMO has appointed Gordon C. McCauley, President and CEO of adMare BioInnovations and Steven Klosk CEO (retired) Cambrex Corporation, to its board of directors. “Mr. Klosk and Mr. McCauley are innovative executives who offer a wealth of experience to the BIOVECTRA Board […]

Read More…

Biovectra Enhances Manufacturing Capacity and Flexibility with ABEC’s CSR® Large-Scale, Single-Use Microbial Fermentation Technology

For immediate release ABEC’s Custom Single Run (CSR) fermentation solutions offer working volumes up to 1,000 liters  Bethlehem, PA, USA, and Charlottetown, CANADA, September 20, 2021 – ABEC, a global provider of integrated solutions and services for biopharmaceutical manufacturing and BIOVECTRA, a CDMO specializing in clinical-to-commercial scale production of high-quality regulated Biologics, Active Pharmaceutical Ingredients, […]

Read More…

Mallinckrodt Agrees to Sell BIOVECTRA Inc. to H.I.G. Capital for $250 Million

Statement from BIOVECTRA President, Oliver Technow, on BIOVECTRA’s sale to H.I.G. Capital: “We are very excited to enter into this new chapter with H.I.G. Capital! Under their stewardship we have a fantastic opportunity to continue building and growing our business right here in Atlantic Canada.” Official press release: Mallinckrodt Agrees to Sell BIOVECTRA Inc. to […]

Read More…

BIOVECTRA Inc. hosts roundtable discussion with Minister Bernadette Jordan and other key Windsor community stakeholders to discuss planned five-year, $144.6 million expansion project

BIOVECTRA Inc. hosts roundtable discussion with Minister Bernadette Jordan and other key Windsor community stakeholders to discuss planned five-year, $144.6 million expansion project Windsor, Nova Scotia, Canada (March 7, 2019) – On March 6, 2019, BIOVECTRA Inc., an Atlantic Canadian Contract Development and Manufacturing Organization (CDMO), hosted a roundtable discussion at its Windsor, Nova Scotia […]

Read More…

BIOVECTRA Inc. Announces the Offer of High Quality, Fully Synthetic cGMP Cannabidiol (CBD) Active Pharmaceutical Ingredient (API)

BIOVECTRA Inc. Announces the Offer of High Quality, Fully Synthetic cGMP Cannabidiol (CBD) Active Pharmaceutical Ingredient (API) Charlottetown, Prince Edward Island, Canada (March 17, 2019) – BIOVECTRA Inc., a U.S. Food and Drug Administration- and Health Canada-inspected and approved Contract Development and Manufacturing Organization (CDMO), announces the offer of high quality, fully synthetic cGMP CBD […]

Read More…

BIOVECTRA Inc. Invests $1.5M in Large-Scale Synthetic Reactor Replacements and Analytical Development Capabilities

BIOVECTRA Inc. Invests $1.5M in Large-Scale Synthetic Reactor Replacements and Analytical Development Capabilities BIOVECTRA Inc., a global Contract Development and Manufacturing Organization (CDMO), today announced new investments in its large-scale synthetic chemistry and analytical development capabilities. To continue serving its client’s cGMP manufacturing needs, BIOVECTRA completed the replacement of two 4,000L vessels used for small […]

Read More…